Latest 10-Q quarterly reports

SideChannel, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, highlighting a decrease in total revenue and significant going concern risks.

Sutro Biopharma's Q2 2026 filing reveals a substantial revenue decrease driven by the termination of the Ipsen collaboration, alongside continued net losses, though clinical development for STRO-004 shows early promise.

TScan Therapeutics reports continued net losses and substantial doubt about its ability to continue as a going concern, with cash reserves expected to fund operations into Q2 2027.

Cypherpunk Technologies Inc. filed its Q2 2026 10-Q, detailing a shift towards a digital asset treasury strategy alongside its ongoing biopharmaceutical research, marked by a substantial unrealized gain on digital assets but also significant operating losses.

HG Holdings, Inc. announced a significant increase in total revenues for the second quarter of 2026, driven by substantial growth in management fees and title insurance operations.

Protalix BioTherapeutics announces a significant surge in revenue and net income for the second quarter of 2026, driven by strong sales of Elfabrio and Elelyso.

Octave Intelligence plc reported a significant net loss of $1.97 billion for the quarter ended June 30, 2026, driven by substantial goodwill and intangible asset impairments totaling over $2.1 billion.

Lexeo Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing clinical trial progress and financial performance, including a net loss of $25.9 million.

Milestone Pharmaceuticals Inc. reports on the commercial launch of CARDAMYST, progress in its AFib-RVR clinical program, and financial updates for the quarter ended June 30, 2026.

WhiteFiber, Inc. reported increased revenues for Q2 2026, but also a widening net loss and significant increases in operating expenses and debt.

Enanta Pharmaceuticals reported a decrease in Q3 2026 revenue to $14.4 million from $18.3 million in the prior year, driven by lower HCV sales, while continuing to invest heavily in its RSV and immunology drug development programs.

Liquidia Corporation reported a substantial increase in product sales driven by YUTREPIA, alongside significant investments in research and development and ongoing litigation.

Unicycive Therapeutics reported a significant increase in net loss for the six months ended June 30, 2026, alongside a setback in its OLC New Drug Application, though it bolstered its cash position through common stock sales.

Cambridge Acquisition Corp. reports on its financial condition and operational activities for the quarter ended June 30, 2026, highlighting income from trust account investments and ongoing efforts to identify a business combination target.

SharonAI Holdings Inc. has filed an amendment to its Q2 2026 Form 10-Q to correct errors in net loss per share and equity balances, reporting a substantial net loss for the period.

GrowGeneration Corp. announced its second quarter 2026 financial results, showing a 5.5% increase in net sales but a continued net loss, alongside a decrease in gross profit margins for its Storage Solutions segment.

Tofutti Brands reported a significant decrease in net sales and a widening net loss for the second quarter of 2026, raising substantial doubt about its going concern status.

SUMA Acquisition Corporation reports on its Q2 2026 financial status, highlighting interest income and operational costs as it continues its search for a business combination target.

Syra Health Corp. announced a significant shift to profitability in its Q2 2026 report, driven by a 23% year-over-year revenue increase and improved gross margins.

Kopin Corporation's Q2 2026 filing reveals a shift to net income for the quarter but continued net loss for the six-month period, alongside ongoing litigation and identified material weaknesses in internal controls.

AECOM's Q3 filing reveals a net loss attributable to the company, a significant drop in gross profit, and a decrease in overall revenue compared to the prior year, though underlying revenue excluding pass-through costs showed growth.

TRG Latin America Acquisitions Corp. files its Q2 2026 Form 10-Q, detailing its financial status as a SPAC and its ongoing search for a business combination.

Wrap Technologies, Inc. announced its second-quarter 2026 financial results, showing a 103% increase in total revenues to $2.1 million, driven by a substantial rise in product sales, though technology-enabled services revenue declined.

Inuvo, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing a substantial decrease in net revenue driven by a strategic reset in its Legacy Search business, while noting growth in its Audience Modeling segment.

Mineralys Therapeutics, Inc. (MLYS) reports a substantial increase in R&D expenses driven by a $200 million upfront payment for a license amendment, alongside securing a $100 million term loan and raising capital through equity offerings.

Auburn National Bancorporation announced a 34% increase in net earnings for the first six months of 2026, driven by higher interest income and improved net interest margin.

Firefly Aerospace Inc. announced a substantial increase in revenue for the second quarter of 2026, driven by its Spacecraft Solutions segment and the integration of SciTec, though net losses widened.

Spartacus Acquisition Corp. II reports on its Q2 2026 activities, highlighting its focus on the TMT sector for a future business combination and detailing its financial position.

Pixelworks, Inc. (PXLW) files its Q2 2026 Form 10-Q, detailing a substantial revenue decrease and operational losses, offset by a significant gain from the sale of its semiconductor business.

KLX Energy Services Holdings, Inc. reported its second quarter 2026 financial results, showing a net loss and detailing a significant upcoming rights offering to address financial obligations.